Loss of RAGE Defense: A Cause of Charcot Neuroarthropathy?
Open Access
- 17 June 2011
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (7), 1617-1621
- https://doi.org/10.2337/dc10-2315
Abstract
OBJECTIVE: This study investigated the relationship between circulating soluble receptor for advanced glycation end products (sRAGE) and parameters of bone health in patients with Charcot neuroarthropathy (CNA). RESEARCH DESIGN AND METHODS: Eighty men (aged 55.3 ± 9.0 years), including 30 healthy control subjects, 30 type 2 diabetic patients without Charcot, and 20 type 2 diabetic patients with stage 2 (nonacute) CNA, underwent evaluations of peripheral and autonomic neuropathy, nerve conduction, markers of bone turnover, bone mineral density, and bone stiffness of the calcaneus. RESULTS: CNA patients had worse peripheral and autonomic neuropathy and a lower bone stiffness index than diabetic or control individuals (77.1, 103.3, and 105.1, respectively; P < 0.05), but no difference in bone mineral density (P > 0.05). CNA subjects also had lower sRAGE levels than control (162 vs. 1,140 pg/mL; P < 0.01) and diabetic (162 vs. 522 pg/mL; P < 0.05) subjects, and higher circulating osteocalcin levels. CONCLUSIONS: CNA patients had significantly lower circulating sRAGE, with an accompanying increase in serum markers of bone turnover, and reduced bone stiffness in the calcaneus not accompanied by reductions in bone mineral density. These data suggest a failure of RAGE defense mechanisms against oxidative stress in diabetes. Future studies should determine if medications that increase sRAGE activity could be useful in mitigating progression to CNA.Keywords
This publication has 25 references indexed in Scilit:
- The RAGE AxisCirculation Research, 2010
- Diabetes and skeletal healthJournal of Diabetes, 2009
- Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligandDiabetologia, 2008
- Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathwaysBone, 2007
- Diabetic Cardiovascular Autonomic NeuropathyCirculation, 2007
- Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblastsArchives of Physiology and Biochemistry, 2007
- Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebraeBone, 2006
- RAGE-NF-?B pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophyActa Neurologica Scandinavica, 2006
- Role of nonenzymatic glycosylation of type I collagen in diabetic osteopeniaJournal of Bone and Mineral Research, 1996
- NEURO-ARTHROPATHY (CHARCOT JOINTS) IN DIABETES MELLITUSMedicine, 1972